DMD and Duchenne muscular dystrophy: ESOs have been shown to promote skipping of exon 23 and concomitant dystrophin expression in skeletal muscles of mdx mice after both local and systemic delivery [8,11-17], and this technology in the context of therapy for DMD has been recently reviewed [18,19].